NEW YORK, Aug. 27, 2015 /PRNewswire/ -- Tripp Levy
PLLC, a leading national securities law firm, announces that a
class action lawsuit has been filed against Northwest
Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the
"Company") (NASDAQ: NWBO) and certain of its officers. The class
action, filed in United States District Court, District of
Maryland, Greenbelt Division, and
docketed under 8:15-cv-02532, is on behalf of a class consisting of
all persons or entities who purchased Northwest Biotherapeutics
securities between March 8, 2013 and
August 20, 2015 inclusive (the "Class
Period").
The Complaint alleges that throughout the Class Period,
Defendants made false and/or misleading statements, as well as
failed to disclose material adverse facts about the Company's
business, operations, and prospects. Specifically, Defendants made
false and/or misleading statements and/or failed to disclose that:
(i) the Company's claims regarding positive results from its
DCVax-Direct Trial were based on preliminary and unconfirmed trial
results; (ii) the DCVax-Direct Trial results on which the Company
reported had not been reviewed or analyzed by the hospitals
conducting the trials; (iii) the Company's statements about
DCVax-Direct were derived from patient case report forms, which the
hospitals were obliged to send to the Company only because it
sponsored the study; (iv) the Company was the subject of an
aggressive stock promotion campaign which included promoters using
fictitious identities and false credentials; (v) German regulators
required additional information from the Company in order for the
Company's DCVax-L Trial to continue uninterrupted; and (vi) as a
result of the above, the Company's financial statements were
materially false and misleading at all relevant times.
If you purchased shares of Northwest and have suffered a loss
from your investment in Northwest common stock and would like to
learn more about this lawsuit, including your ability to
potentially recover your losses, please contact us either by email
at contact@tripplevy.com or by telephone at (800) 511-7037 or visit
our website at www.tripplevy.com/participate-in-an-action. In
addition, if you wish to serve as a representative party, you must
move the Court no later than 60 days from the date of the filing of
the Complaint. You can join this class action to potentially
recover your losses by contacting us at
www.tripplevy.com/participate-in-an-action.
Tripp Levy PLLC is a leading national securities and shareholder
rights law firm representing both individual and institutional
shareholders and, along with its affiliate, have recovered billions
of dollars for shareholders. Tripp Levy PLLC is affiliated
with Milberg LLP. The National Law Journal has named Milberg
one of the "50 Elite Trial Lawyer Firms" and one of the "50 Leading
Plaintiff Firms in America."
Attorney advertising. Prior results do not indicate a
similar outcome.
Tripp Levy PLLC
New York, New York
Toll free: 800-511-7037
International: 602-241-2841
Email: contact@tripplevy.com
www.tripplevy.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/northwest-biotherapeutics-alert-national-securities-law-firm-announces-filing-of-lawsuit-on-behalf-of-northwest-shareholders-to-recover-losses-and-encourages-investors-to-contact-law-firm-for-more-information-300134102.html
SOURCE Tripp Levy PLLC